Systemic therapy in metastatic pancreatic adenocarcinoma: current practice and perspectives

Lisa Lellouche, Lola-Jade Palmieri, Solène Dermine, Catherine Brezault, Stanislas Chaussade and Romain Coriat

Abstract: Major breakthroughs have been achieved in the management of metastatic pancreatic ductal adenocarcinoma (PDAC) with FOLFIRINOX (5-fluorouracil + irinotecan + oxaliplatin) and gemcitabine plus nab-paclitaxel approved as a first-line therapy, although the prognosis is still poor. At progression, patients who maintain a good performance status (PS) can benefit from second-line chemotherapy. To address the concern of achieving tumor control while maintaining a good quality of life, maintenance therapy is a concept that has now emerged. After a FOLFIRINOX induction treatment, maintenance with 5-fluorouracil (5-FU) seems to offer a promising approach. Although not confirmed in large, prospective trials, gemcitabine alone as a maintenance therapy following induction treatment with gemcitabine plus nab-paclitaxel could be an option, while a small subset of patients with a germline mutation of breast cancer gene (BRCA) can benefit from the polyadenosine diphosphate-ribose polymerase (PARP) inhibitor olaparib. The rate of PDAC with molecular alterations that could lead to a specific therapy is up to 25%. The Food and Drug Administration (FDA) recently approved larotrectinib for patients with any tumors harboring a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, and pembrolizumab for patients with a mismatch repair deficiency in a second-line setting, including PDAC. Research focused on targeted therapy and immunotherapy is active and could improve patients’ outcomes in the near future.

Keywords: chemotherapy, FOLFIRINOX, maintenance, microsatellite instability, nab-paclitaxel, olaparib, pancreatic carcinoma, PARP inhibitors, pembrolizumab, quality of life

Introduction
Pancreatic ductal adenocarcinoma (PDAC) was the fourth leading cause of death by cancer in the United States and the seventh worldwide in 2019.1,2 Its 5-year survival rate is 9%, which is the lowest of all solid tumors. As its incidence is increasing, PDAC is expected to become the second most common cause of cancer-related death by 2030.3 Although surgical resection is the only curative treatment, only 15–20% of patients are candidates for surgery.4 At diagnosis, most patients have a locally-advanced or a metastatic disease. Medical treatment remains the cornerstone for these patients.

In the 1990s, gemcitabine monotherapy became the first-line standard-of-care for metastatic PDAC, after a randomized trial demonstrated its superiority; both in terms of its clinical benefit and overall survival (OS) compared with 5-fluorouracil (5-FU).5 Major breakthroughs were achieved in 2011 and 2013,6,7 when two large phase III trials showed a clear benefit resulting from a regimen comprising 5-FU, irinotecan and oxaliplatin (FOLFIRINOX) in combination with gemcitabine and nab-paclitaxel, versus gemcitabine monotherapy. The median OS was significantly improved; however, both treatments were associated with higher rates of adverse effects and...
triggered limiting toxicities. These chemotherapies are now considered as the two main first-line options for patients with metastatic PDAC and a good performance status (PS).

Considering the interesting survival rates provided by these chemotherapies but also their limiting toxicities, the need for maintenance therapy has emerged. Maintenance therapy has recently been evaluated with chemotherapy or targeted therapies. Furthermore, the potential of actionable molecular targets in PDAC patients has garnered significant interest.8 The Food and Drug Administration (FDA) recently approved the use of pembrolizumab, an anti-programmed-death receptor 1 (anti-PD-1), for patients with any microsatellite instability (MSI) high tumors, including PDAC. Immunotherapy is being studied in larger indications in PDAC.

This review aims to outline the management of metastatic PDAC, from current standard-of-care to recent data on maintenance therapy, and discuss potential future therapeutic directions.

**Current standard-of-care**

**First-line therapy**

Until 2011, gemcitabine monotherapy was the standard-of-care in metastatic PDAC. This was based on a randomized trial which showed significant improvement in OS and clinical benefit compared with 5-FU monotherapy.5 The median OS provided by gemcitabine as a single-agent did not exceed 6 months (5.65 months versus 4.41 months with 5-FU, \( p = 0.0025 \)) (Table 1). In 2013, a large phase III study randomized 861 patients without any treatment for a metastatic disease and compared with gemcitabine and gemcitabine-plus-nab-paclitaxel.7 Gemcitabine-plus-nab-paclitaxel was associated with a significant benefit in OS (8.5 versus 6.7 months, HR 0.72, \( p < 0.001 \)), PFS (5.5 versus 3.7 months, HR 0.69, \( p < 0.001 \)) and ORR (23% versus 7%, HR 3.19, \( p < 0.001 \)). The incidence of grade 3 or higher neutropenia, leukopenia, and peripheral neuropathy was significantly higher in the gemcitabine-plus-nab-paclitaxel group (respectively 38%, 31%, and 17%). In contrast to the phase III trial of FOLFIRINOX versus gemcitabine, there was no upper age restriction in this study. Ten percent of patients were at least 75 years of age, and 8% of patients had a Karnofsky PS score between 60% and 70%, corresponding to a PS ECOG of 2.
Table 1. Clinical trials (randomized phase II and phase III trials) in metastatic PDAC.

| Drug tested                        | Setting                              | Population              | n  | Outcomes                                                                                   |
|------------------------------------|--------------------------------------|-------------------------|----|--------------------------------------------------------------------------------------------|
| Conroy et al.¹                   | FOLFIRINOX versus gemcitabine        | First-line Metastatic PDAC | 342| **mOS 11.1** versus 6.9 months [HR 0.57; 95% CI [0.45–0.73]; p < 0.001]                     |
|                                    |                                      |                         |    | **mPFS 6.4** versus 3.3 months [HR 0.47; 95% CI [0.37–0.59]; p < 0.001]                      |
| Von Hoff et al.²                  | Gemcitabine-nab paclitaxel versus gemcitabine | First-line Metastatic PDAC | 861| **mOS 8.5** versus 6.7 months [HR 0.72; 95% CI [0.62–0.83]; p < 0.001]                     |
|                                    |                                      |                         |    | **mPFS 5.5** versus 3.7 months [HR 0.69; 95% CI [0.58–0.82]; p < 0.001]                      |
| Moore et al.³                     | Gemcitabine-erlotinib versus gemcitabine | First-line Metastatic PDAC | 569| **mOS 6.24** versus 5.91 months [HR 0.82; 95% CI [0.69–0.89]; p = 0.038]                    |
|                                    |                                      |                         |    | **mPFS 3.75** versus 3.55 months [HR 0.77; 95% CI [0.64–0.92]; p = 0.004]                    |
| Pelzer et al.¹⁰                   | OFF versus best supportive care      | Second-line Metastatic PDAC progressing on gemcitabine | 46 | **mOS 9.09** versus 7.90 months [HR 0.50; 95% CI [0.27–0.95]; p = 0.031]                    |
| Oettle et al.¹¹                   | OFF versus 5-FU                      | Second-line Metastatic PDAC progressing on gemcitabine | 168| **mOS 5.9** versus 3.3 months [HR 0.66; 95% CI [0.48–0.91]; p < 0.01]                      |
| Gill et al.¹²                     | mFOLFOX6 versus LV5FU2               | Second-line Metastatic PDAC progressing on gemcitabine | 108| **mOS 6.1** versus 9.9 months [HR 1.78; 95% CI [1.08–2.93]; p = 0.024]                     |
| Yoo et al.¹³                      | mFOLFIRI-3 versus mFOLFOX            | Second-line Metastatic PDAC progressing on gemcitabine | 61 | 6-months survival rate 27% [95% CI [13–46]] versus 30% [95% CI [15–49]]                   |
| Wang-Gillam et al.¹⁴              | Nal-IRI plus LV5FU2 versus LV5FU2    | Second-line Metastatic PDAC progressing on gemcitabine | 417| **mOS 6.2** versus 4.2 months [HR 0.67; 95% CI [0.49–0.92]; p = 0.012]                     |
| Dahan et al.¹⁵                    | FOLFIRINOX (arm A) versus FOLFIRINOX 4 months then LV5FU2 (arm B) versus gemcitabine and FOLFIRI-3 alternating every 2 months (arm C) | Maintenance Metastatic PDAC | 273| **mOS 10.1 months [arm A] 11.2 months [arm B]**                                            |
|                                    |                                      |                         |    | **mPFS 3.2** versus 2 months [HR 0.51; 95% CI [0.29–0.89]; p < 0.01]                        |
| Reni, 2013¹²                     | Sunitinib versus observation         | Maintenance Metastatic PDAC without progression after 6 months of first-line chemotherapy | 56 | **mOS 10.6** versus 9.2 months [HR 0.71; 95% CI [0.40–1.26]; p = 0.11]                     |
| Golan et al.¹⁶                    | Olaparib versus placebo              | Maintenance Metastatic PDAC without progression after first-line platinum-based chemotherapy and BRCA1 or BRCA2 germline mutation | 154| **mPFS 7.4** versus 3.8 months [HR 0.53; 95% CI [0.35–0.82]; p = 0.004]                    |
|                                    |                                      |                         |    | **mOS 18.9** versus 18.1 months [HR 0.91; 95% CI [0.56–1.46]; p = 0.68]                     |

5-FU, 5-fluorouracil; BRCA1/2, breast cancer gene 1/2; CI, confidence interval; FOLFIRI-3, irinotecan 90 mg/m² at days 1 and 3, 5-FU 2000 mg/m² over 46 hours; FOLFIRINOX, 5-fluorouracil, irinotecan and oxaliplatin; HR, hazard ratio; n, number of patients randomized; LV5FU2, 5-FU bolus 400 mg/m² and 5-FU 2400 mg/m² over 48 hours; mFOLFIRI-3, irinotecan 70 mg/m² at days 1 and 3, 5-FU 2000 mg/m² over 46 hours; mFOLFOX6, oxaliplatin 85 mg/m², 5-FU bolus 400 mg/m² and 5-FU 2400 mg/m² over 48 hours; mOS, median overall survival; mPFS, median progression free survival; Nal-IRI, liposomal irinotecan, 5-FU; OFF, oxaliplatin, folinic acid and 5-FU; PDAC, pancreatic ductal adenocarcinoma.
No prospective randomized trial compared with FOLFIRINOX versus gemcitabine-plus-nab-paclitaxel in a first-line approach. However, retrospective studies did not report any major outcome differences between the two treatment regimens. In a review of 16 retrospective studies including 3813 patients, the pooled risk of death (HR = 0.99, 95% CI 0.84–1.16, p = 0.9) and progression (HR 0.88, 95% CI 0.71–1.1, p = 0.26) was similar between FOLFIRINOX and gemcitabine-nab-paclitaxel; however, the median OS was slightly higher in the FOLRINOX arm [mean weighted OS difference 1.15 months, 95% CI (0.08–2.22), p = 0.03]. Neutropenia and febrile neutropenia occurred significantly more often in the FOLFIRINOX arm. Therefore, gemcitabine-plus-nab-paclitaxel and FOLFIRINOX are both endorsed as first-line therapies by the European Society for Medical Oncology (ESMO) and the American National Comprehensive Cancer Network (NCCN) in patients with metastatic PDAC. A phase I/II trial recently evaluated the combination of liposomal irinotecan, 5-FU, and oxaliplatin (NALIRIFOX) in 32 untreated patients, and reported median PFS and OS of 9.2 (95% CI 7.69–11.69) and 12.6 (95% CI 8.74–18.69) months, respectively. A phase III randomized trial comparing gemcitabine plus nab-paclitaxel to NALIRIFOX in a first-line setting is currently underway (ClinicalTrials.gov identifier: NCT 04083235).

Sequential treatment of gemcitabine-plus-nab-paclitaxel and FOLFIRINOX (GABRINOX) in a first-line setting has been evaluated in a prospective, single-arm phase II trial in 58 patients. The results were promising, with an impressive ORR (63.2%, 95% CI 49.3–75.5) and a prolonged mean OS (mOS) (17.8 months, 95% CI 11.7–21.3). Interestingly, the grade 3 peripheral neuropathy rate was low (5.2%).

The combination of cisplatin and gemcitabine (cisplatin 25 mg/m², gemcitabine 600 mg/m²) with or without the polyadenosine diphosphate-ribose polymerase (PARP) inhibitor veliparib was evaluated in 50 patients with previously untreated advanced PDAC with a germline mutation of BRCA/PALB2 in a phase II randomized trial. It revealed an impressive ORR (74.1%) in the cisplatin/gemcitabine arm, 65.2% in the cisplatin/gemcitabine-plus-veliparib
arm, \( p=0.55 \). The median PFS and OS were also longer than survival rates reported in PDAC trials [median PFS 10.1 months (95% CI, 6.7–11.5), median OS 15.5 months (95% CI, 12.2–24.3) in the cisplatin/gemcitabine arm]. No difference was found in terms of median OS, PFS, and ORR between the two arms. Toxicities in the cisplatin/gemcitabine arm appeared manageable. Therefore, the remarkable ORR achieved with the gemcitabine-plus-cisplatin regimen, combined with its relatively low toxicity, due to doses in this regimen lower than the doses of other indications, makes it a valuable option in the subset of patients with a \textit{BRCA}/\textit{PALB2} germline mutation.

Erlotinib, an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, is the only targeted therapy to date that has shown, in combination with gemcitabine, a statistically significant improvement in OS in a phase III trial in 2007. A total of five hundred and sixty-nine patients with locally advanced or metastatic PDAC and no prior treatment for metastatic disease were randomized to receive gemcitabine-plus-placebo or gemcitabine-plus-erlotinib. Both the median OS and PFS were significantly higher in the gemcitabine-plus-erlotinib group, although the improvement was modest (median OS 6.24 versus 5.91 months, \( p=0.038 \); PFS 3.75 versus 3.55 months, \( p=0.004 \)). Despite FDA approval and NCCN endorsement, the very modest survival improvement achieved by the combination of erlotinib and gemcitabine undermines its potential to be the most valuable option for first-line treatment of metastatic PDAC. This combination is also not recommended by the 2015 ESMO guidelines.

In metastatic PDAC, chemotherapy has proven its efficacy in terms of median PFS, OS, and clinical benefit. Despite a large number of studies that have evaluated targeted therapies or chemotherapies, the only two regimens which showed a clinically relevant benefit in terms of survival and which are validated worldwide are the triplet with 5-FU, oxaliplatin, and irinotecan (FOLFIRINOX) and the doublet with gemcitabine-plus-nab-paclitaxel.

**Maintenance therapy**

FOLFIRINOX and gemcitabine-plus-nab-paclitaxel are associated with toxicities that often lead to dose-reductions and limit their long-term use. In a study by Conroy et al., the median number of cycles of FOLFIRINOX administrated was 10. A retrospective study on 2565 patients with metastatic PDAC in 9 European countries found that dose modifications during the treatment course occurred in 21% of cases for FOLFIRINOX and 20.5% of cases for gemcitabine-plus-nab-paclitaxel. These limiting toxicities and the objective of maintaining a good quality-of-life stress the need for maintenance strategies.

Alternating induction with FOLFIRINOX and maintenance with 5-FU has been assessed in the PANOPTIMOX/PRODIGE 35 randomized phase II trial. There were two hundred and seventy-three patients which were randomized in three arms: FOLFIRINOX for 12 cycles (arm A), FOLFIRINOX for eight cycles then 5-FU until disease progression (arm B), or a sequential treatment, alternating between FOLFIRI and gemcitabine every 2 months (arm C). Six month PFS appeared nearly similar in arm A and arm B (47% and 44% respectively) whereas it was lower in arm C (34%). The median OS was also very similar in arm A and arm B (10.1 months 11.2 months respectively), but the 18-month OS rate was higher in arm B (28% versus 18.5%, \( p<0.05 \) in an interim analysis). Surprisingly, the grade 3 or 4 neurotoxicity rate was the highest in the maintenance therapy group (19% versus 10% in arm A), probably because of a higher cumulative oxaliplatin dose after reintroduction in this arm. Capecitabine, an oral prodrug of 5-FU, was evaluated in 2016 in a retrospective study as maintenance therapy after an induction treatment by FOLFIRINOX. Thirty patients without progression after 4-8 cycles of FOLFIRINOX were included. The median PFS on maintenance therapy was 5 months. At reintroduction of the intravenous chemotherapy, the median PFS was 10 months and the median OS was 17 months.

Recently, a retrospective multicentre study evaluated real-life clinical practice of FOLFIRINOX de-escalation and maintenance strategies in 321 patients with metastatic or locally-advanced PDAC. A total of forty-six percent of patients received a maintenance therapy after a median number of nine cycles of FOLFIRINOX. The maintenance therapies were FOLFIRI (45%), oral or 5-FU (35%), and FOLFOX (17%). The median OS for the entire cohort was 16.1 months (95% CI 13.7–20.3). The median OS was similar between those who received 5-FU and those who received FOLFIRI (16.6 versus 18.7 months, \( p=0.86 \)), as was PFS (10.1 versus 9.0 months,
Grade 3 or 4 toxicities were more frequent with FOLFIRI maintenance therapy than with 5-FU (41% versus 22%, \( p = 0.03 \)).

Maintenance with gemcitabine could be interesting after gemcitabine plus nab-paclitaxel induction and has been studied in a prospective study that evaluated maintenance with gemcitabine alone after three cycles of gemcitabine plus nab-paclitaxel in 36 patients aged 70 and over. This study showed a six-month diseases control rate (DCR) of 61\% (95% CI, 45–77) and a median OS of 13.4 months (95% CI, 11.1–16.7). The median number of cycles of gemcitabine alone was three (range, 2–9 cycles) and nab-paclitaxel was reintroduced for eight patients after disease progression. Seventeen percent of patients developed sensory neuropathy, although they never reached grade 3. A ‘stop-and-go’ approach, consisting of suspending nab-paclitaxel when patients had grade 3 sensory neuropathy and then reintroducing it at disease progression, was evaluated in a small retrospective study. Here, the continuation of nab-paclitaxel after its reintroduction resulted in a mean second PFS of 2.2 months (range 1–4 months).

In a randomized phase II PACT-12 trial which included 56 patients with stable disease after first-line chemotherapy, sunitinib, an oral multi-targeted tyrosine kinase inhibitor (TKI) targeting the vascular endothelial growth factor receptor (VEGF) and the platelet-derived growth factor receptor (PDGFR), was associated with a significantly longer median PFS than observation [3.2 versus 2 months, HR 0.51; 95% CI (0.29–0.89); \( p < 0.01 \)].

Olaparib is a PARP inhibitor that has shown efficacy in patients with a germline BRCA mutation and ovarian or breast cancer. Its efficacy as a maintenance therapy in patients with metastatic PDAC who had not progressed after a platinum-based chemotherapy and a germline BRCA 1 or 2 mutation was recently evaluated in the phase III POLO trial (Figure 2). Of the 3,315 screened patients, only 247 had a germline BRCA mutation, which is consistent with the 4–7% frequency reported in the literature. A total of one hundred and fifty-seven patients were randomized to receive either olaparib or placebo. The median PFS was significantly improved in the olaparib group [7.4 versus 3.8 months, HR 0.53; 95% CI (0.35–0.82); \( p = 0.004 \)]. Grade 3 or 4 toxicities occurred in 49% of patients in the olaparib group.

Final OS results were recently presented and showed no difference between the two arms (19.0 months in the olaparib arm versus 19.2 months in the placebo arm, \( p = 0.3487 \)), whereas the 36-month OS rates were higher in the olaparib group (33.9% versus 17.8%). The authors highlight that the study was underpowered to detect a difference in OS; even though cross-over was not allowed, 26% of patients in the placebo arm received a PARP inhibitor, which may have biased the results. It should be noted that olaparib was compared with a placebo, although discontinuation of chemotherapy at stability is not the current standard-of-care. Given the use of a placebo as a comparator and the conflicting PFS and OS results, it remains unclear whether olaparib is the most beneficial option for maintenance therapy in patients with a BRCA germline mutation. This also raises the issue of germline testing for patients at diagnosis of metastatic PDAC.
Maintenance therapy is a daily necessity and appears feasible for example with LV5FU2 (5-FU bolus 400 mg/m² and 5-FU 2400 mg/m² over 48 hours) after at least 8–12 cycles of FOLFIRINOX. Gemcitabine alone after induction treatment with gemcitabine-plus-nab-paclitaxel could also reduce limiting toxicities but probably requires further validations by larger studies. The optimal number of cycles of combination chemotherapy remains an issue.

Second-line therapy
In the FOLFIRINOX versus gemcitabine trial, only 46.7% of heavily-selected patients underwent a second-line treatment at progression. In a meta-analysis that included 71 second-line studies and 3,112 patients, active treatment compared with the best supportive care (BSC) showed a significantly longer median OS (4.6 versus 2.5 months respectively, \( p = 0.02 \)). Retrospective studies tried to identify prognostic factors to select patients that could benefit from a second-line therapy. In a retrospective analysis of 90 patients, an ECOG PS of 0 or 1, an albumin level of at least 35 g/l, and response from a first-line therapy seemed associated with a better outcome regarding OS. In another retrospective analysis of 280 patients who received second-line treatment for PDAC, Karnofsky PS, carbohydrate antigen 19-9 (CA 19-9) at the beginning of second-line therapy, and the duration of first-line treatment significantly influenced median OS.

In 2009, the alkylating agent glufosfamide failed to improve OS compared with BSC in a second-line setting in a phase III trial. In 2011, a phase III trial compared BSC alone versus an OFF regimen (folinic acid 200 mg/m², 5-FU 2000 mg/m² over 24 hours on days 1, 8, 15, 22 and oxaliplatin 85 mg/m²) regimens were evaluated in a prospective cohort of 63 patients as a second-line therapy for metastatic PDAC resistant to gemcitabine and platinum-salts. The DCR was 39.7% while the median OS was 6.6 months. The FOLFIRI regimen has also been evaluated in a phase II trial comparing a modified FOLFIRI-3 regimen (irinotecan 70 mg/m² on days 1 and 3, leucovorin 400 mg/m², and 5-FU 2000 mg/m²) to mFOLFOX6 in 61 patients with gemcitabine-refractory advanced PDAC. The DCR [23% versus 7.90, \( p = 0.031 \), HR 0.50, 95% CI (0.27–0.95) respectively]. The OFF regimen was later compared with folinic acid and fluorouracil in the CONKO-003 phase III trial which included 186 patients. The median OS was improved in the OFF group [5.9 versus 3.3 months, HR 0.66, 95% CI (4.1–7.4)] as well as the median time to progression [2.9 versus 2.0 months, HR 0.68, 95% CI (0.50–0.94), \( p = 0.019 \)]. Data from 27 patients who received FOLFOX as second-line treatment among patients included in the FIRGEM trial, which compared with gemcitabine alone to gemcitabine alternating with FOLFIRI3 as a first-line treatment, were prospectively analyzed in an observational cohort study. The median OS and PFS from the start of the second-line therapy were 4.3 and 1.7 months, respectively. In contrast, the addition of oxaliplatin to 5-FU reduced the OS in the PANCREOX phase III trial. A total of one hundred and eight patients were randomized to receive either LV5FU2 (bolus of 5-FU followed by a 2400 mg/m² continuous infusion) or biweekly mFOLFOX6 (bolus of 5-FU 400 mg/m² followed by a continuous infusion of 2400 mg/m² and oxaliplatin 85 mg/m²). While the ORR and PFS did not significantly differ between the two groups, the median OS was significantly lower in the mFOLFOX6 group [6.1 versus 9.9 months, HR 1.78; 95% CI (1.08–2.93), \( p = 0.024 \)]. This lack of benefit may be explained by greater toxicity in the mFOLFOX6 arm, with more patients withdrawn from the study due to adverse events (63% versus 11%), and the more frequent use of subsequent treatment lines after progression in the LV5FU2 arm (23% versus 7%). Therefore, the data on the combination of 5-FU and platinum as second-line approaches are controversial.

FOLFIRI-1 (irinotecan 180 mg/m², leucovorin 400 mg/m², 5-FU 400 mg/m² bolus, then an infusion of 2400 mg/m²) and FOLFIRI-3 (irinotecan 100 mg/m² on days 1 and 3, leucovorin 400 mg/m², and an infusion of 2400 mg/m² of 5-FU without bolus) regimens were evaluated in a prospective cohort of 63 patients as a second-line therapy for metastatic PDAC resistant to gemcitabine and platinum-salts. The DCR was 39.7% while the median OS was 6.6 months. The FOLFIRI regimen has also been evaluated in a phase II trial comparing a modified FOLFIRI-3 regimen (irinotecan 70 mg/m² on days 1 and 3, leucovorin 400 mg/m², and 5-FU 2000 mg/m²) to mFOLFOX in 61 patients with gemcitabine-refractory advanced PDAC. The DCR [23% versus 7.90, \( p = 0.031 \), HR 0.50, 95% CI (0.27–0.95) respectively]. The OFF regimen was later compared with folinic acid and fluorouracil in the CONKO-003 phase III trial which included 186 patients. The median OS was improved in the OFF group [5.9 versus 3.3 months, HR 0.66, 95% CI (4.1–7.4)] as well as the median time to progression [2.9 versus 2.0 months, HR 0.68, 95% CI (0.50–0.94), \( p = 0.019 \)]. Data from 27 patients who received FOLFOX as second-line treatment among patients included in the FIRGEM trial, which compared with gemcitabine alone to gemcitabine alternating with FOLFIRI3 as a first-line treatment, were prospectively analyzed in an observational cohort study. The median OS and PFS from the start of the second-line therapy were 4.3 and 1.7 months, respectively. In contrast, the addition of oxaliplatin to 5-FU reduced the OS in the PANCREOX phase III trial. A total of one hundred and eight patients were randomized to receive either LV5FU2 (bolus of 5-FU followed by a 2400 mg/m² continuous infusion) or biweekly mFOLFOX6 (bolus of 5-FU 400 mg/m² followed by a continuous infusion of 2400 mg/m² and oxaliplatin 85 mg/m²). While the ORR and PFS did not significantly differ between the two groups, the median OS was significantly lower in the mFOLFOX6 group [6.1 versus 9.9 months, HR 1.78; 95% CI (1.08–2.93), \( p = 0.024 \)]. This lack of benefit may be explained by greater toxicity in the mFOLFOX6 arm, with more patients withdrawn from the study due to adverse events (63% versus 11%), and the more frequent use of subsequent treatment lines after progression in the LV5FU2 arm (23% versus 7%). Therefore, the data on the combination of 5-FU and platinum as second-line approaches are controversial.
In a retrospective analysis of 181 patients who progressed on gemcitabine-plus-nab-paclitaxel, mOS and mPFS were higher in patients treated with a platinum-based doublet than those treated with an irinotecan-based doublet (free irinotecan or liposomal irinotecan). However, this did not reach statistical significance (mOS 10.3 versus 8.2 months, \(p = 0.713\); mPFS 4.0 versus 3.3 months, \(p = 0.494\)).

A liposomal formulation of irinotecan (nal-IRI) was tested as a second-line therapy after a gemcitabine-based first-line in the phase III NAPOLI-1 trial. A total of four hundred and seventeen patients were randomized into three groups: nal-IRI monotherapy, nal-IRI plus LV5FU2, or LV5FU2 monotherapy. The median OS was significantly longer in the nal-IRI plus LV5FU2 group, as compared with LV5FU2 monotherapy [6.2 versus 4.2 months, HR 0.67, 95% CI (0.49–0.92); \(p = 0.012\)]. There was no difference in median OS between the nal-IRI monotherapy group and the LV5FU2 group. The ORR was higher in the nal-IRI plus LV5FU2 group than in the LV5FU2 monotherapy group (17% versus 1%, \(p = 0.0001\)). Nal-IRI plus LV5FU2 is currently recommended by ESMO (European Society for Medical Oncology) and NCCN guidelines for patients who have progressed after a gemcitabine-based first-line therapy. It should be noted that Nal-IRI is not available in many parts of the world, and, while it has been shown in preclinical studies to achieve higher intratumoral levels of irinotecan and its active metabolite SN-38, no randomized trial has compared Nal-IRI-plus-5-FU with FOLFIRI. Interestingly, no differences in OS and PFS were found in a retrospective study which compared Nal-IRI/5FU with FOLFIRI in patients with advanced PDAC who had received prior gemcitabine-based chemotherapy (mOS 7.1 versus 6.7 months, mPFS 4.1 versus 3.1 months). Similar rates of grade 3 or 4 toxicities were observed between the two groups.

No prospective randomized studies on FOLFIRINOX or modified FOLFIRINOX as a second-line therapy have been conducted. One retrospective study of 27 patients that had progressed after a gemcitabine monotherapy found a median OS of 8.5 months and a DCR of 63%. Similar findings were reported in another retrospective study conducted on 18 patients. Recently, retrospective analysis on 52 patients who had progressed after gemcitabine-plus-nab-paclitaxel and underwent a second-line with a modified FOLFIRINOX identified a median OS of 22.5 months for metastatic disease. A modified FOLFIRINOX (oxaliplatin 65 mg/m², irinotecan 135 mg/m², 5-FU 2000 mg/m² continuous infusion with no bolus) has been evaluated in a prospective single-arm Korean trial in 39 patients who had progressed after gemcitabine-based chemotherapy. The median OS and PFS were 8.5 months (95% CI 5.6–11.4) and 3.8 months (95% CI 1.5–6), respectively. In daily practice, triplet chemotherapy in a second-line setting is often perceived as too toxic.

Several retrospective studies have evaluated gemcitabine as a single agent in second-line therapy after FOLFIRINOX failure, and reported a median OS from 3.6 to 5.7 months. Recently, a phase II trial assessed the efficacy and safety of the combination of gemcitabine-plus-nab-paclitaxel after FOLFIRINOX in 30 patients under 75 years-old with an ECOG PS of 0 or 1. The ORR and DCR were 13.3% and 46.7%, respectively. The median OS from the beginning of the second-line treatment was 7.6 months. Similar results were found in a prospective cohort of 57 patients who received gemcitabine/nab-paclitaxel after FOLFIRINOX failure (ORR 17.5%, DCR 58%, median OS 8.8 months). In a retrospective study in 103 patients with advanced PDAC who received gemcitabine-plus-nab-paclitaxel after FOLFIRINOX failure, the mOS and mPFS were 9.8 months and 4.6 months, respectively. In a recent meta-analysis including 16 studies, the DCR was higher for patients treated with gemcitabine-plus-nab-paclitaxel compared with single-agent gemcitabine (53.5% versus 30.2%, \(p < 0.001\)) after FOLFIRINOX failure. Although the vast majority of available data are from retrospective trials, gemcitabine-plus-nab-paclitaxel in selected patients who have progressed after platinum-based therapy seems to be associated with improved outcomes when compared with gemcitabine monotherapy.

The use of a second-line treatment could benefit selected patients who maintain a good general condition. For these patients, nal-IRI plus 5-FU is currently endorsed by American and European guidelines. Although data on FOLFIRINOX in a...
second-line setting are limited, it could be an option, as well as gemcitabine-plus-nab-paclitaxel after platinum-based first-line therapy. One should note that clinical practices regarding the choice of combination chemotherapy in the first- or in the second-line setting is currently affected by national regulations and drug reimbursement policies.

**Future directions**

It is estimated that the rate of pancreatic tumors with molecular alterations for which there is clinical or preclinical evidence of a benefit from a specific therapy is up to 25%.\(^6^1\)\(^-^6^5\)

Recently, tumor samples from 1028 patients referred to the Know Your Tumour program, a program of molecular profiling for patients with PDAC launched by the Pancreatic Cancer Action Network (PanCAN), were analyzed.\(^8\) A total of one hundred and eighty-nine patients out of 617 had actionable molecular alteration and 46 patients received a molecularly-matched treatment. The median OS was significantly longer in the matched therapy group than in the group of patients who had molecular alterations and who received unmatched therapy [2.58 versus 1.51 years; HR 0.42; 95% CI (0.26–0.68), \(p=0.0004\)].

**KRAS pathway**

Mutations in the *Kirsten rat sarcoma viral oncogene homology* (*KRAS*) oncogene are found in more than 90% of PDAC.\(^6^4\) It is well-demonstrated that *KRAS* mutation predicts resistance to EGFR targeted-therapy in colon cancer,\(^6^6\)\(^,\)\(^6^7\) whereas its implication in PDAC is more controversial.

Erlotinib, an inhibitor of EGFR tyrosine kinase, has shown a statistically significant but modest improvement on OS in combination with gemcitabine for metastatic PDAC, in the NCIC CTG PA.3 phase III trial, but *KRAS* mutation was not analyzed.\(^9\) In a retrospective study of 136 patients with locally-advanced or metastatic PDAC who received first-line gemcitabine-based chemotherapy with or without erlotinib, the median OS was significantly longer in the subgroup of *KRAS* wild-type patients treated with gemcitabine-erlotinib (9.7 versus 5.2 months, \(p=0.002\)).\(^6^8\) There was no difference in OS based on the *KRAS* mutation status in the subgroup of patients treated with gemcitabine without erlotinib (7.0 versus 7.0 months; \(p=0.121\)). In contrast, the retrospective analysis of 146 tumor samples from patients included in the NCIC CTG PA.3 trial did not reveal any significant interaction between *KRAS* mutation status and OS in patients treated with gemcitabine/erlotinib.\(^6^9\) Similarly, no association between *KRAS* mutation status and outcomes was found in a prospective randomized Taiwanese trial evaluating gemcitabine with or without erlotinib in 88 treatment-naive patients.\(^7^0\) In contrast, in patients treated with gemcitabine-plus-erlotinib, the mOS, mPFS, and DCR were significantly higher in those with EGFR mutations than in those with no EGFR mutations (mOS 8.7 versus 6.0 months, \(p=0.044\); mPFS median 5.9 versus 2.4 months, \(p=0.004\); DCR 85% versus 33%, \(p=0.001\)). Therefore, data on *KRAS* and *EGFR* mutations status as predictive biomarkers for inhibitor of EGFR tyrosine kinase efficacy are uncertain and require more evaluation.

Cetuximab, an anti-EGFR monoclonal antibody, failed to improve survival in combination with gemcitabine in a phase III, which was not stratified according to *KRAS* mutation status.\(^7^1\) Nimotuzumab, another anti-EGFR monoclonal antibody, has shown efficacy in combination with gemcitabine in a first-line setting for OS and PFS in a phase IIb randomized, placebo-controlled trial including 192 patients.\(^7^2\) Both median OS and PFS were significantly higher in the gemcitabine-plus-nimotuzumab group (median OS 8.6 versus 6.0 months; HR 0.69; \(p=0.03\); median PFS 5.1 versus 3.4 months; HR 0.68; \(p=0.02\)). At 12 months, patients with a *KRAS* wild-type status had a significantly better OS rate in the nimotuzumab group than in the placebo group (53.8% versus 15.8%; HR 0.32; \(p=0.026\)).

Other approaches to target *KRAS* by inhibiting its downstream signaling pathways, such as the Ras-Raf-MEK-ERK pathway, have been attempted. The addition of trametinib, a selective mitogen-activated protein kinase (MEK) inhibitor, to gemcitabine did not improve OS in a phase II trial.\(^7^3\) Selumetinib, another MEK inhibitor, also failed to improve OS in comparison with capecitabine in a second-line setting.\(^7^4\)

*KRAS* encodes for a guanosine triphosphatase (GTPase) protein, which cycles between an inactive guanoside diphosphate (GDP)-bound state and an active guanosine triphosphate (GTP)-bound state. Oncogenic mutations of *KRAS*...
 impair GTPase protein activity, resulting in the accumulation of its active form. The $\text{KRAS} \text{G12C}$ mutation is rare in PDAC (1% of PDAC), but recently, small molecules that specifically and irreversibly inhibit the $\text{KRAS} \text{G12C}$ mutation have garnered interest. $\text{KRAS} \text{G12C}$ inhibitors lead to the trapping of the mutant KRAS protein in its inactive GDP-bound state, and have shown durable tumor regression in preclinical studies.\cite{76,77} The $\text{KRAS} \text{G12C}$ inhibitor Sotorasib (AMG 510) showed promising activity in a phase I clinical trial in 129 pre-treated patients including 12 PDAC.\cite{78} Among the 28 patients with other tumor types, 4 had a partial confirmed response (including one with PDAC) while 17 had stable disease. A large phase Ib trial evaluating sotorasib as a single agent or in combination for patients with advanced solid tumors with $\text{KRAS} \text{G12C}$ mutation is currently ongoing (ClinicalTrials.gov identifier: NCT04185883).

**PARP inhibitors**

The $\text{BRCA} 1$ and 2, ATM serine/threonine kinase ($\text{ATM}$), $\text{PALB2}$, ATR serine/threonine kinase ($\text{ATR}$), and fanconi anaemia complementation group A (FANC) genes are involved in homologous recombination (HR) repair mechanisms which play a key role in repairing double-strand breaks (DSB) of DNA. Approximately four- to seven percent of patients with PDAC harbor a germline mutation of $\text{BRCA} 1$ or 2.\cite{35,37} PARP is involved in repairing single-strand DNA breaks (SSB) and its inhibition results in the accumulation of SSB and eventually conversion to DSB, which in case of HR deficiency leads to cell death.

Olaparib monotherapy was evaluated in a phase II trial involving 298 patients who progressed on prior chemotherapy with advanced cancer and a germline $\text{BRCA}$ mutation, including 23 PDAC.\cite{79} The ORR was 21.7% in PDAC (95% CI, 7.5–43.7) and the median PFS was 4.6 months. No difference was found concerning ORR between patients who did or did not receive prior platinum-therapy.

The efficacy of rucaparib, another PARP inhibitor (PARPi), as a single agent in patients with metastatic PDAC who received one or two previous lines of chemotherapy, has been investigated in a phase II trial conducted on 19 patients with germline ($n = 16$) or somatic ($n = 3$) $\text{BRCA}$ mutations.\cite{80} Enrolment was stopped because the study did not meet its primary endpoint, with a DCR of 32% and an ORR of 15.8%. Interestingly, none of the four tumors of the patients who responded to rucaparib had progressed with prior platinum therapy, which is consistent with previous findings regarding platinum sensitivity conferred by DNA-damage repair (DDR) mutations.\cite{65} A retrospective analysis of patients with advanced PDAC who received platinum-based therapy in a first-, second-, or third-line setting found a significantly higher ORR in patients harboring a $\text{BRCA}$ or $\text{PALB2}$ mutation, in comparison with control patients (58% versus 21%, $p = 0.0022$), as well as a longer median PFS (10.1 months versus 6.9 months, $p = 0.0068$).\cite{81} Veliparib was tested in monotherapy in a phase II trial including 16 patients with pre-treated PDAC and a germline $\text{BRCA}$ mutation.\cite{82} No confirmed radiological response was observed. It should be noted that 88% percent of patients had previously been treated with platinum-based therapy, while 64.3% of them experienced disease progression while on this regimen. Recently, a phase I/II study of veliparib, in combination with FOLFOX for previously untreated or treated metastatic PDAC patients with HR genes mutation or a suggestive family history, showed an ORR of 26%.\cite{83} In the subgroup of patients without prior platinum-based therapy, ORR and DCR were 32% and 64% respectively, while the ORR for previously platinum-treated patients was 7% and DCR was 14%. The highest ORR in this study was found in the subgroup of patients with an HR gene mutation who had not been previously exposed to platinum salts (ORR 57%). This raises the issue of the association between platinum-sensitivity and response to PARPi’s in patients displaying disease progression under prior chemotherapy, as restoration of the HR system has been described and could be a resistance mechanism to platinum and PARPi therapy.\cite{84} The addition of veliparib to the combination of gemcitabine and cisplatin in a first-line setting did not improve ORR, median PFS, and OS in a phase II randomized trial for previously untreated patients with an advanced PDAC and a $\text{BRCA/PALB2}$ germline mutation.\cite{26} Therefore, the contribution of veliparib to platinum-based therapy in a first-line setting for patients harboring a $\text{BRCA}$ or $\text{PALB2}$ mutation is uncertain.

Olaparib has proven its efficacy as a maintenance therapy for metastatic PDAC that had not progressed during first-line platinum-based chemotherapy in patients with a germline $\text{BRCA}$ mutation.\cite{16} However, the place of PARPi’s as
maintenance therapy is not clearly-defined, as it has not been compared with cytotoxic chemotherapy in this setting. Moreover, it is still unclear whether PARPi could benefit patients with somatic mutation in the HR genes. Rucaparib is currently being tested (ClinicalTrials.gov identifier: NCT03140670) (Table 2) as maintenance therapy in a single-arm phase II study in patients with a somatic or germline mutation in BRCA1, BRCA2, or PALB2 and a platinum-sensitive PDAC. Early results are encouraging, with a DCR of 89.5%. A phase II study evaluating olaparib as a maintenance therapy in patients with a somatic BRCA mutation has recently started (ClinicalTrials.gov identifier: NCT04348045) (Table 2).

PARPi’s are a promising addition to metastatic PDAC drugs for patients with a BRCA mutation, but many questions remain, such as the appropriate timing of their use and their efficacy in patients with a somatic BRCA mutations.

**Other explored pathways**

Among the small, but non-negligible proportion of PDAC with no KRAS mutation (8–12%62,65), several molecular alterations are therapeutically targetable. These include the fusion in the neurotrophin receptor tyrosine kinase (NRTK) and ROS1 fusions, NRG1 fusions, ALK rearrangement and BRAF mutations, have been described in various solid tumors.93 Genomic profiling of 3,170 locally advanced or metastatic PDAC identified 5 ALK-rearrangement tumors (0.16%) in young patients (<50 years old).97 The ongoing basket trial MATCH (ClinicalTrials.gov identifier: NCT02465060) (Table 2) will evaluate crizotinib, an ALK protein inhibitor, among other therapies for various tumors.

Gene fusions involving neuregulin-1 (NRG1) activate the human epidermal growth factor (HER2-HER3) receptor tyrosine kinase pair, leading to the pathological activation of its downstream signaling pathway, such as phosphoinositide 3-kinase (PI3K)/ protein kinase B (AKT). The HER-family kinase inhibitor afatinib has shown some efficacy for these tumors.94,95 In a whole-genome and transcriptome sequencing of 47 PDAC, Jones et al. detected three patients with NRG1 fusion-positive tumors, all of them KRAS wild-type.96 Two of them were treated with afatinib. Both had a radiologic response at 3 months. One experienced disease progression 5 months after initiation of afatinib. A phase II trial (NCT04410653) (Table 2) of afatinib for advanced solid NRG1-rearranged tumors, including PDAC, is scheduled to start shortly. Zenocutuzumab, a bispecific monoclonal antibody that binds to HER 2 and HER 3 receptors and blocks the interaction of NRG1 fusion protein with its receptor HER3, has been shown to induce a response in tumors harboring NRG1 fusions in preclinical and early clinical studies.97,98 A phase I/II trial evaluating zenocutuzumab in patients with various solid tumors harboring a NRG1 fusion is currently underway (ClinicalTrials.gov identifier: NCT02912949).

Fusions in the NRTK gene family leads to a chimeric tropomyosin receptor kinase (TRK) fusion protein and is an oncogenic driver in various types of tumors. Larotrectinib, a TRK inhibitor, has shown efficacy in a phase I–II trial including 1 PDAC, with an ORR of 75%,90 and is approved by the FDA for any tumor harboring an NTRK gene fusion. Entrectinib, another TRK-inhibitor showed an ORR of 57% (95% CI, 43.2–70.8%) in an analysis of 3 phase I–II trials with 3 PDAC.91 Fusions in the NTRK family gene is rare (<1% in every solid tumor92), but given the benefits from TRK inhibitors, molecular testing for NTRK gene fusions could be considered in patients with advanced PDAC and an ECOG PS of 0 or 1 without any other therapeutic proposition.

Translocation of the anaplastic lymphoma Kinase (ALK) gene results in constitutive activation of ALK, which encodes for a TRK protein and has been described in various solid tumors.93 Genomic profiling of 3,170 locally advanced or metastatic PDAC tumors, all of them KRAS wild-type,86–89 but many questions remain, such as the appropriate timing of their use and their efficacy in patients with a somatic BRCA mutations.92

The mitochondrial metabolism in tumor cells has been shown to be particularly important for PDAC cells.99 Devimistat (CPI-613) targets the mitochondrial tricarboxylic acid (TCA) cycle, through the inhibition of two of its major enzyme complexes, pyruvate dehydrogenase complex (PDC) and α-ketoglutarate dehydrogenase (KGDH). Encouraging results of a phase I study on CPI-613 combined with FOLFIRINOX with an ORR of 61% (95% CI, 36–83%)100 led to the start of the AVENGER phase III trial, which evaluated modified FOLFIRINOX with or without CPI-613 (ClinicalTrials.gov identifier: NCT03504423) in the first-line setting.101 The combination of CPI-613 and gemcitabine-plus-nab-paclitaxel was also evaluated in a phase I trial, resulting in 50% response rate.102 Therefore, early clinical trials suggest the efficacy of CPI 613 in combination with chemotherapy, but these findings require further confirmations.
Immunotherapy

High microsatellite instability (MSI-h) or mismatch repair deficiency (dMMR) is a rare occurrence in PDAC (~ 0.5–1%). MSI-high tumors, characterized by the strong expression of tumor neoantigens and immune check-point ligands, have been shown to benefit from immune check-point inhibitors. The anti-PD1 pembrolizumab...
has been approved by the FDA for all MSI-h/ dMMR tumors, and is endorsed by the NCCN in a second-line setting. In a next-generation sequencing (NGS) of 833 patients with PDAC, MSI-h/ dMMR tumors were found in seven patients (~0.84%), of whom five were treated with anti-PD1 or anti-PDL1. Four of them had a response or a stable disease.\textsuperscript{105} The KEYNOTE-158 phase II study assessed the efficacy of pembrolizumab for non-colorectal MSI-h/dMMR tumors in a second-line setting or over.\textsuperscript{107} Two hundred and thirty-three patients with 27 tumor types, including 22 patients with PDAC, were included. The median OS and PFS were 23.5 months (95% CI, 13.5 months to not reached) and 4.1 months (95% CI, 2.4 to 4.9 months) respectively, while the ORR was 34.3% (95% CI, 28.3–40.8%). However, the ORR [18.2%, 95% CI (5.2–40.3%)], median OS [4 months, 95% CI (2.1–9.8)], and median PFS [2.1 months, 95% CI (1.9–3.4)] were lower for PDAC patients than for the entire cohort.

Anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) has also been evaluated in PDAC. In a phase II trial, 27 patients with advanced PDAC received ipilimumab but with no objective response.\textsuperscript{108} A randomized phase II trial of the anti-PD-L1 durvalumab with or without the anti-CTLA4 tremelimumab in a second-line setting was also disappointing, with an ORR of 3.1% (95% CI, 0.008–16.22) for combination therapy and 0% (95% CI, 0.00–10.58) for monotherapy.\textsuperscript{109}

The combination of immune checkpoint inhibitors and cytotoxic chemotherapy for metastatic PDAC has also been investigated in phase I studies. While a phase II study evaluating pembrolizumab in combination with either gemcitabine-plus-nab-paclitaxel or FOLFIRINOX is underway (ClinicalTrial.gov identifier: NCT04447092) (Table 2), the addition of tremelimumab and durvalumab to gemcitabine and nab-paclitaxel did not improve OS, PFS, and ORR in the CCTG PA.7 phase II randomized trial.\textsuperscript{110}

Several retrospective studies have demonstrated an association between tumor mutational burden (TMB), a quantitative assessment of the number of somatic mutations within a tumor genome, and response to immune checkpoint blockade, notably in melanoma and non-small cell lung cancer (NSCLC).\textsuperscript{111–113} Plasma TMB of patients included in the CCTG PA.7 were analyzed retrospectively. In patients with high-TMB (with a threshold of \(\geq 9\) mut/Mb), there was a trend toward a decreasing HR, favoring the combination of chemotherapy and immunotherapy (HR 0.30, 90% CI 0.06–1.37), in contrast to patients in the low TMB subgroup (HR 0.97, 90% CI 0.73–1.29).\textsuperscript{114} It should be noted that only 4.6% of patients had a plasma TMB \(\geq 9\) mut/Mb. High-TMB may be a predictive biomarker of tumor response to checkpoint inhibition for metastatic PDAC, but these data require prospective confirmation.

Cancer vaccines have also been investigated in PDAC, with mixed results.\textsuperscript{115} To date, the largest study evaluating the vaccines GVAX and CRS 207 in PDAC was disappointing, with no difference in OS with or without GVAX.\textsuperscript{116} The addition of nivolumab to GVAX/CRS 207 did not improve OS in a phase II randomized trial in pre-treated PDAC patients.\textsuperscript{117} A randomized phase II trial will assess the efficacy of GVAX and CRS 207 in combination with dual immune checkpoint inhibition (ClinicalTrials.gov identifier: NCT03190265) (Table 2). Another area of development is chimeric antigen receptor (CAR)-T cells therapy, which uses genetically-engineered T cells directed to specific cancer-associated antigens. Results from preclinical and phase I studies in PDAC are promising,\textsuperscript{118–120} and several phase I/II trials on CAR-T cells for various solid tumors, including PDAC, are currently ongoing (ClinicalTrials.gov identifiers: NCT02744287, NCT03159819) (Table 2).

Immunotherapy as a maintenance therapy for metastatic PDAC is an option currently being evaluated in different trials (Table 2).

One possible explanation for the difficulty in achieving a significant and sustained response from immunotherapy for PDAC is the abundance of an immunosuppressive stroma through cancer-associated fibroblast activation and a relatively low level of neoantigens compared with other solid tumors. Future perspectives for immunotherapy will probably combine checkpoint inhibitors with other drugs, or remodel the PDAC microenvironment \textit{via} depletion of pro-tumorigenic immune cells.\textsuperscript{121}

\textbf{Conclusions}

Undisputable progress has been made in the management of metastatic PDAC, with a significant subset of patients now achieving stabilization or a response with combination chemotherapies in the first-line management of...
their disease. As survival increases slowly and because quality of life is an absolute priority, the concept of maintenance therapy has emerged for metastatic PDAC. Continuing low-dose cytotoxic chemotherapy is a valid option, but switching to PARP inhibitors should be considered in patients with a germline mutation of BRCA 1 or 2. The question of whether PARP inhibitors could benefit patients with a somatic mutation of BRCA 1 or 2 remains a concern that future trials may answer. Besides maintenance therapy, research is ongoing, and a better understanding of the unique characteristics inherent to PDAC and its immunosuppressive microenvironment should shortly lead to the development of novel agents that specifically target signaling pathways and genetic alterations present in patients with PDAC and could achieve substantial survival benefits.

**Conflict of interest statement**

L-J.P. has conflicts of interest with Servier, Amgen, Merck, MSD, Keocyt. S.D. has conflicts of interest with Mylan, Amgen. C.B. has conflicts of interest with IPSEN. S.C. has conflicts of interest with AAA. R.C. has conflicts of interest with AAA, Bayer, Servier, Ipsen, Novartis and Keocyt. All other authors have no conflict of interest to declare.

**Funding**

The authors received no financial support for the research, authorship, and/or publication of this article.

**ORCID iD**

Lola-Jade Palmieri https://orcid.org/0000-0002-8540-9344

**References**

1. Siegel RL, Miller KD and Jemal A. Cancer statistics, 2019. *CA Cancer J Clin* 2019; 69: 7–34.
2. Rawla P, Sunkara T and Gaduputi V. Epidemiology of pancreatic cancer: global trends, etiology and risk factors. *World J Oncol* 2019; 10: 10–27.
3. Rahib L, Smith BD, Aizenberg R, *et al.* Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. *Cancer Res* 2014; 74: 2913–2921.
4. Fogel EL, Shahda S, Sandrasegaran K, *et al.* A multidisciplinary approach to pancreas cancer in 2016: a review. *Am J Gastroenterol* 2017; 112: 537–554.
5. Burris HA, Moore MJ, Andersen J, *et al.* Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. *J Clin Oncol* 1997; 15: 2403–2413.
6. Conroy T, Desseigne F, Ychou M, *et al.* FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. *N Engl J Med* 2011; 364: 1817–1825.
7. Von Hoff DD, Ervin T, Arena FP, *et al.* Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. *N Engl J Med* 2013; 369: 1691–1703.
8. Pishvaian MJ, Blais EM, Brody JR, *et al.* Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial. *Lancet Oncol* 2020; 21: 508–518.
9. Moore MJ, Goldstein D, Hamm J, *et al.* Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol* 2007; 25: 1960–1966.
10. Pelzer U, Schwaner I, Stieler J, *et al.* Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. *Eur J Cancer* 2011; 47: 1676–1681.
11. Oettle H, Riess H, Stieler JM, *et al.* Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. *JCO* 2014; 32: 2423–2429.
12. Gill S, Ko Y-J, Cripps C, *et al.* PANCREOXS: a randomized phase III study of fluorouracil/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy. *JCO* 2016; 34: 3914–3920.
13. Yoo C, Hwang JY, Kim J-E, *et al.* A randomised phase II study of modified FOLFOXIRI 3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. *Br J Cancer* 2009; 101: 1658–1663.
14. Wang-Gillam A, Li C-P, Bodoky G, *et al.* Nanoliposomal irinotecan with fluorouracil.
and folic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 2016; 387: 545–557.

15. Dahan L, Phelip JM, Le Malicot K, et al. FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRO.3 for first-line treatment of metastatic pancreatic cancer: a randomized phase II trial (PRODIGE 35-PANOPTIMOX). JCO 2018; 36: 4000.

16. Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med 2019; 381: 317–327.

17. Stein SM, James ES, Deng Y, et al. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. Br J Cancer 2016; 114: 737–743.

18. Mahaseth H, Brutcher E, Kauh J, et al. Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. Pancreas 2013; 42: 1311–1315.

19. Usón Junior PLS, Rother ET, Maluf FC, et al. Meta-analysis of modified FOLFIRINOX regimens for patients with metastatic pancreatic cancer. Clin Colorectal Cancer 2018; 17: 187–197.

20. Nakazawa J, Otsuka T, Shimokawa M, et al. A multicenter retrospective study of gemcitabine plus nab-paclitaxel or FOLFIRINOX in metastatic pancreatic cancer: NAPOLEON study. Ann Oncol 2019; 30: iv17–iv18.

21. Kang J, Hwang I, Yoo C, et al. Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis. Invest New Drugs 2018; 36: 732–741.

22. Kim S, Signorovitch JE, Yang H, et al. Comparative effectiveness of nab-paclitaxel plus gemcitabine vs FOLFIRINOX in metastatic pancreatic cancer: a retrospective nationwide chart review in the United States. Adv Ther 2018; 35: 1564–1577.

23. Pusceddu S, Ghidini M, Torchio M, et al. Comparative effectiveness of gemcitabine plus nab-paclitaxel and FOLFIRINOX in the first-line setting of metastatic pancreatic cancer: a systematic review and meta-analysis. Cancers (Basel) 2019; 11: 484.

24. Dean A, Bekaii-Saab T, Boland PM, et al. 191P first-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: results from a phase I/II study. Ann Oncol 2020; 31: S1313–S1314.

25. Assenat E, De La Fouchardiere C, Mollevi C, et al. Sequential treatment with nab-paclitaxel plus gemcitabine and folfoxirin in metastatic pancreatic adenocarcinoma: GABRINOX phase II results. JCO 2018; 36: 4109.

26. O’Reilly EM, Lee JW, Zalupski M, et al. Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation. J Clin Oncol 2020; 38: 1378–1388.

27. Taieb J, Prager GW, Melisi D, et al. First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study. ESMO Open 2020; 5: e000587.

28. Reure J, Follana P, Gal J, et al. Effectiveness and tolerability of maintenance capcetibine administrated to patients with metastatic pancreatic cancer treated with first-line FOLFIRINOX. Oncology 2016; 90: 261–266.

29. Chevalier H, Vienot A, Lièvre A, et al. FOLFIRINOX de-escalation in advanced pancreatic cancer (aPC): a multicenter real-life study. JCO 2020; 38: 4639.

30. Petrioli R, Torre P, Pesola G, et al. Gemcitabine plus nab-paclitaxel followed by maintenance treatment with gemcitabine alone as first-line treatment for older adults with locally advanced or metastatic pancreatic cancer. J Geriatr Oncol. Epub ahead of print 27 August 2019. DOI: 10.1016/j.jgo.2019.08.008.

31. Relias V, Maloney A, Smith MH, et al. Does “OPTINAB” strategy (“stop-and-go”) work in treatment of advanced pancreatic cancer (APC) with nab-paclitaxel-gemcitabine? Cancer Chemother Pharmacol 2017; 80: 371–375.

32. Reni M, Cereda S, Milella M, et al. Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II randomised trial. Eur J Cancer 2013; 49: 3609–3615.

33. Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2018; 379: 2495–2505.

34. Robson M, Im S-A, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 2017; 377: 523–533.
35. Ghiorzo P. Genetic predisposition to pancreatic cancer. *World J Gastroenterol* 2014; 20: 10778–10789.

36. Holter S, Borgida A, Dodd A, *et al.* Germline *BRCA* mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma. *JCO* 2015; 33: 3124–3129.

37. Friedenson B. *BRCA1* and *BRCA2* pathways and the risk of cancers other than breast or ovarian. *MedGenMed* 2005; 7: 60.

38. Golan T, Hammel P, Reni M, *et al.* Overall survival from the phase 3 POLO trial: maintenance olaparib for germline *BRCA*-mutated metastatic pancreatic cancer. *JCO* 2021; 39: 378.

39. Nagrial AM, Chin VT, Sjoquist KM, *et al.* Second-line treatment in inoperable pancreatic adenocarcinoma: a systematic review and synthesis of all clinical trials. *Crit Rev Oncol Hematol* 2015; 96: 483–497.

40. Kim ST, Choi YJ, Park KH, *et al.* A prognostic model to identify patients with advanced pancreas adenocarcinoma who could benefit from second-line chemotherapy. *Clin Oncol (R Coll Radiol)* 2012; 24: 105–111.

41. Sinn M, Dälken L, Striefler JK, *et al.* Second-line treatment in pancreatic cancer patients: who profits?—results from the CONKO study group. *Pancreas* 2016; 45: 601–605.

42. Ciuleanu TE, Pavlovsky AV, Bodoky G, *et al.* A randomised phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine. *Eur J Cancer* 2009; 45: 1589–1596.

43. Zaanan A, Trouilloud I, Markoutsaki T, *et al.* FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study. *BMC Cancer* 2014; 14: 441.

44. Neuzillet C, Hentic O, Rousseau B, *et al.* FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts. *World J Gastroenterol* 2012; 18: 4533–4541.

45. Merz V, Cavaliere A, Messina C, *et al.* Multicenter retrospective analysis of second-line therapy after gemcitabine plus nab-paclitaxel in advanced pancreatic cancer patients. *Cancers* 2020; 12: 1131.

46. Wang-Gillam A, Hubner RA, Siveke JT, *et al.* NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: final overall survival analysis and characteristics of long-term survivors. *Eur J Cancer* 2019; 108: 78–87.

47. Kalra AV, Kim J, Klinz SG, *et al.* Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodruk conversion. *Cancer Res* 2014; 74: 7003–7013.

48. Tossey JC, Reardon J, VanDeuseen JB, *et al.* Comparison of conventional versus liposomal irinotecan in combination with fluorouracil for advanced pancreatic cancer: a single-institution experience. *Med Oncol* 2019; 36: 87.

49. Assaf E, Verlinde-Carvalho M, Delbaldo C, *et al.* 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma. *Oncology* 2011; 80: 301–306.

50. Lee MG, Lee SH, Lee SJ, *et al.* 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy. *Chemotherapy* 2013; 59: 273–279.

51. Das A, Dean AP and Higgs D. Modified FOLFIRINOX as a second-line treatment in pancreatic adenocarcinoma patients with poor performance status. *JCO* 2019; 37: e15796.

52. Kim JH, Lee S-C, Oh SY, *et al.* Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study. *Cancer Commun (Lond)* 2018; 38: 32.

53. da Rocha Lino A, Abrahão CM, Brandão RM, *et al.* Role of gemcitabine as second-line therapy after progression on FOLFIRINOX in advanced pancreatic cancer: a retrospective analysis. *J Gastrointest Oncol* 2015; 6: 511–515.

54. Viaud J, Brac C, Artru P, *et al.* Gemcitabine as second-line chemotherapy after folfirinox failure in advanced pancreatic adenocarcinoma: a retrospective study. *Dig Liver Dis* 2017; 49: 692–696.

55. Gilabert M, Chanez B, Rho YS, *et al.* Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma. *Medicine (Baltimore)* 2017; 96: e6544.

56. Sarabi M, Mais L, Oussaid N, *et al.* Use of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinoma. *Oncol Lett* 2017; 13: 4917–4924.
57. Mita N, Iwashita T, Uemura S, et al. Second-line gemcitabine plus nab-paclitaxel for patients with unresectable advanced pancreatic cancer after first-line FOLFIRINOX failure. *J Clin Med* 2019; 8: 761.

58. Portal A, Pernot S, Tougeron D, et al. Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after folfirinox failure: an AGEO prospective multicentre cohort. *Br J Cancer* 2015; 113: 989–995.

59. Yoo C, Jeong H, Chae H, et al. Efficacy and safety of second-line nab-paclitaxel plus gemcitabine (nab-P+GEM) after progression on first-line FOLFIRINOX in advanced pancreatic ductal adenocarcinoma (PDAC): multicenter retrospective analysis. *JCO* 2020; 38: 689.

60. de Jesus VHF, Camandaroba MPG, Calsavara VF, et al. Systematic review and meta-analysis of gemcitabine-based chemotherapy after FOLFIRINOX in advanced pancreatic cancer. *Ther Adv Med Oncol* 2020; 12: 17588392090540.

61. Aguirre AJ, Nowak JA, Camarda ND, Moffitt RA, Ghazani AA, Hazar-Rethinam M, et al. Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. *Cancer Discov* 2018; 8: 1096–111. https://doi.org/10.1158/2159-8290.CD-18-0275.

62. Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. *Nature* 2016; 531: 49–52.

63. Australian Pancreatic Cancer Genome Initiative Biankin AV, Waddell N, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. *Nature* 2012; 491: 399–405.

64. Lowery MA, Jordan EJ, Basturk O, et al. Real-time genomic profiling of ductal adenocarcinoma: potential actionability and correlation with clinical phenotype. *Clin Cancer Res* 2017; 23: 6094–6100.

65. Waddell N, Pajic M, Patch A-M, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. *Nature* 2015; 518: 495–501.

66. Lièvre A, Bachet J-B, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. *Cancer Res* 2006; 66: 3992–3995.

67. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. *N Engl J Med* 2008; 359: 1757–1765.

68. Kim ST, Lim DH, Jang K-T, et al. Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy. *Mol Cancer Ther* 2011; 10: 1993–1999.

69. da Cunha Santos G, Dhani N, Tu D, et al. Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3. *Cancer* 2010; 116: 5599–5607.

70. Wang JP, Wu C-Y, Yeh Y-C, et al. Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial. *Oncotarget* 2015; 6: 18162–18173.

71. Philip PA, Benedetti J, Corless CL, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. *J Clin Oncol* 2010; 28: 3605–3610.

72. Schultheis B, Reuter D, Ebert MP, et al. Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study. *Ann Oncol* 2017; 28: 2429–2435.

73. Infante JR, Somer BG, Park JO, et al. A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. *Eur J Cancer* 2014; 50: 2072–2081.

74. Bodoky G, Timcheva C, Spigel DR, et al. A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 ARRY-142886) versus capcitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. *Invest New Drugs* 2012; 30: 1216–1223.

75. Hobbs GA, Der CJ and Rossman KL. RAS isoforms and mutations in cancer at a glance. *J Cell Sci* 2016; 129: 1287–1292.

76. Waddell N, Patch A-M, Dhillon AS, et al. KRASG12C inhibition with sotorasib in KRAS mutant cancers with a covalent G12C-specific inhibitor. *Cell* 2018; 172: 578–589.e17.

77. Hong DS, Fakih MG, Strickler JH, et al. KRASG12C inhibition with sotorasib in advanced solid tumors. *N Engl J Med* 2020; 383: 1207–1217.
79. Kaufman B, Shapiro-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 2015; 33: 244–250.

80. Shroff RT, Hendifar A, McWilliams RR, et al. Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation. JCO Precis Oncol 2018; 2018: 1–15.

81. Wattenberg MM, Asch D, Yu S, et al. Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation. Br J Cancer 2020; 122: 590–591.

82. Lowery MA, Kelsen DP, Capanu M, et al. Overcoming platinum and PARP-inhibitor resistance in ovarian cancer. Cancers 2020; 12: 1607.

83. Pishvaian MJ, Wang H, He AR, et al. A phase I/II study of veliparib in patients with previously treated BRCA-mutated pancreatic ductal adenocarcinoma. Eur J Cancer 2018; 89: 19–26.

84. McMullen M, Karakasis K, Madariaga A, et al. Clinical benefit of entrectinib for patients with metastatic pancreatic cancer who harbor NTRK and ROS1 fusions. JCO 2018; 36: 521.

85. Binder KAR, Mick R, O’Hara M, et al. Abstract CT234: A phase II, single arm study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic mutation in BRCA1, BRCA2 or PALB2. Cancer Res 2019; 79: CT234.

86. Pishvaian MJ, Rolfo CD, Liu SV, et al. Clinical benefit of entrectinib for patients with metastatic pancreatic cancer who harbor NTRK and ROS1 fusions. JCO 2018; 36: 521.

87. Singh AD, Ali SM, Lacy J, et al. Identification of targetable ALK rearrangements in pancreatic ductal adenocarcinoma. J Natl Compr Canc Netw 2017; 15: 555–562.

88. Guan M, Bender RJ, Pishvaian MJ, et al. Molecular and clinical characterization of BRAF mutations in pancreatic ductal adenocarcinomas (PDACs). JCO 2018; 36: 214.

89. Heining C, Horak P, Uhrig S, et al. NRG1 fusions in KRAS wild-type pancreatic cancer. Cancer Discov 2018; 8: 1087–1095.

90. Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018; 378: 731–739.

91. Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol 2020; 21: 271–282.

92. Cocco E, Scaltriti M and Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol 2018; 15: 731–747.

93. Hallberg B and Palmer RH. The role of the ALK receptor in cancer biology. Ann Oncol 2016; 27: iii4–iii15.

94. Gay ND, Wang Y, Beadling C, et al. Durable response to afatinib in lung adenocarcinoma harboring NRG1 gene fusions. J Thorac Oncol 2017; 12: e107–e110.

95. Jones MR, Lim H, Shen Y, et al. Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer. Ann Oncol 2017; 28: 3092–3097.

96. Jones MR, Williamson LM, Topham JT, et al. NRG1 gene fusions are recurrent, clinically actionable gene rearrangements in KRAS wild-type pancreatic ductal adenocarcinoma. Clin Cancer Res 2019; 25: 4674–4681.

97. Geuijen CAW, De Nardis C, Maussang D, et al. Unbiased combinatorial screening identifies a bispecific IgG1 that potently inhibits HER3 signaling via HER2-guided ligand blockade. Cancer Cell 2018; 33: 922–936.e10.

98. MCLA-128 fights NRG1 fusion–positive cancers. Cancer Discov 2019; 9: 1636.

99. Birsoy K, Possemato R, Lorbear FK, et al. Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. Nature 2014; 508: 108–112.

100. Alistar A, Morris BB, Desnoyer R, et al. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. Lancet Oncol 2017; 18: 770–778.

101. Philip PA, Buyse ME, Alistar AT, et al. A phase III open-label trial to evaluate efficacy and safety of CPI-613 plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas. Future Oncol 2019; 15: 3189–3196.

102. Alistar AT, Morris B, Harrison L, et al. A single-arm, open-label, phase I study of CPI-613 (Devimistat) in combination with gemcitabine and nab-paclitaxel for patients with locally advanced or metastatic pancreatic adenocarcinoma. JCO 2020; 38: 4635.
103. Latham A, Srinivasan P, Kemel Y, et al. Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer. JCO 2019; 37: 286–295.

104. Singhi AD, George B, Greenbowe JR, et al. Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers. Gastroenterology 2019; 156: 2242–2253.e4.

105. Hu ZI, Shia J, Studler ZK, et al. Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and recommendations. Clin Cancer Res 2018; 24: 1326–1336.

106. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017; 357: 409–413.

107. Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 2020; 38: 1–10.

108. Royal RE, Levy C, Turner K, et al. Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother 2010; 33: 828–833.

109. O’Reilly EM, Oh D-Y, Dhani N, et al. Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol 2019; 5: 1431.

110. Renouf DJ, Loree JM, Knox JJ, et al. Predictive value of plasma tumor mutation burden (TMB) in the CCTG PA.7 trial: Gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs. GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC). JCO 2021; 39: 411.

111. Le DT, Lutz E, Uram JN, et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother 2013; 36: 382–389.

112. royal RE, Levy C, Turner K, et al. Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother 2010; 33: 828–833.

113. Le DT, Lutz E, Uram JN, et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother 2013; 36: 382–389.

114. Le DT, Picozzi VJ, Ko AH, et al. Results from a phase IIb, randomized, multicenter study of GVAX pancreas and CRS-207 compared with chemotherapy in adults with previously treated metastatic pancreatic adenocarcinoma (ECLIPSE Study). Clin Cancer Res 2019; 25: 5493–5502.

115. Tsujikawa T, Crocenzi T, Durham JN, et al. Evaluation of cyclophosphamide/GVAX pancreas followed by listeria-mesothelin (CRS-207) with or without nivolumab in patients with pancreatic cancer. Clin Cancer Res 2020; 26: 3578–3588.

116. Adusumilli PS, Cherkassky L, Villena-Vargas J, et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med 2014; 6: 261ra151.

117. Maliar A, Servais C, Waks T, et al. Redirected T cells that target pancreatic adenocarcinoma antigens eliminate tumors and metastases in mice. Gastroenterology 2012; 143: 1375–1384.e5.

118. Beatty GL, O’Hara MH, Lacey SF, et al. Activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial. Gastroenterology 2018; 155: 29–32.

119. Mota Reyes C, Teller S, Muckenhuber A, et al. Neoadjuvant therapy remodels the pancreatic cancer microenvironment via depletion of protumorigenic immune cells. Clin Cancer Res 2020; 26: 220–231.